Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data

Anika Therapeutics, Inc.

2025-Q3 EPS reported -$0.78 revenue$82,204,000

Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.
Commercial Channel rev up 22% YoY; Integrity procedures on track to double in 2025; J&J extends Monovisc license to 2031.
Commencing $15M share repurchase via 10b5-1 plan expected to complete by June 2026.
Filed final Hyalofast PMA module; Phase III trial missed primary endpoints but showed significant secondary endpoint benefits.
Hyalofast used in >35K patients globally; Breakthrough Device Designation; post-hoc analyses showed statistical significance in KOOS Pain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.